They also significantly reduce phosphorylation of the ryanodine receptor (RyR) at the S2814 site and lower the risk of triggered activity and atrial arrhythmias by suppressing calcium leakage (153), thereby reflecting their antiarrhythmic properties
Strnad J, McDonnell PA, Riexinger DJ, Mapelli C, Cheng L, Gray H, et al
Semaglutide May Be Considered When A patient is an appropriate candidate for GLP-1 therapy and needs medical support for appetite, weight, blood sugar, and cardiometabolic risk
Part of that difference comes down to a hormone most people have never heard of: GLP-1
All compounds sold by Solatide Biosciences are supplied strictly for in-vitro laboratory and analytical research use only